Article

Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier function

2023-08-24

Abstract excerpt

Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. Blood vessels are in direct contact with high plasma concentrations of BRAFi, but effects of the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5d19eaf2-da35-5cd3-88ca-ce63e5150f04
DOI: 10.1101/2023.08.24.554606

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier functionDOI 10.1101/2023.08.24.554606Read

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function.Semantic proximity Read

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read

Biological challenges of BRAF inhibitor therapy.Semantic proximity Read

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Semantic proximity Read

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma.Semantic proximity Read

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.Semantic proximity Read

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.Semantic proximity Read

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022Semantic proximity Read

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant MelanomaSemantic proximity Read

RAF inhibitors that evade paradoxical MAPK pathway activation.Semantic proximity Read